Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity

Area of Science:

• Oncology
• Immunotherapy
• Virology

Background:

• Oncolytic viruses, proteasome inhibitors, and NK-cell immunotherapy are established monotherapies for glioblastoma.
• Previous research has not explored the combination of these three therapeutic modalities.

Purpose of the Study:

• To evaluate the synergistic effects of combining oncolytic viruses, proteasome inhibitors, and NK-cell immunotherapy against glioblastoma.
• To investigate the underlying mechanisms of cell death induced by the combination therapy.

Main Methods:

• Treatment of glioblastoma models with oncolytic viruses and proteasome inhibitors.
• Assessment of NK-cell mediated cytotoxicity and cell death pathways (necroptosis).
• Evaluation of survival rates in preclinical glioblastoma models.

Main Results:

• Combined treatment induced necroptotic cell death in oncolytic virus-infected glioblastoma cells.
• The combination therapy significantly enhanced NK-cell immunotherapy efficacy.
• Prolonged survival was observed in glioblastoma models treated with the synergistic combination.

Conclusions:

• The combination of oncolytic viruses, proteasome inhibitors, and NK-cell immunotherapy represents a promising synergistic strategy for glioblastoma treatment.
• Induction of necroptosis is a key mechanism mediating the enhanced therapeutic effect.